Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henlius Raises Stakes In Denosumab Race With Phase I Completion

HLX14 Denosumab Biosimilar Scores PK Trial Win; Submissions Expected Later This Year

Executive Summary

Shanghai Henlius Biotech announced the successful completion of a Phase I study of its biosimilar HLX14 to Prolia/Xgeva, paving the way for EU and US approval applications later in 2024.

You may also be interested in...



Sandoz Enters Canada With First Denosumab Biosimilar

Sandoz has truly established its position as the frontrunner in the denosumab race after a Canadian approval, but the path to the US market has been hindered by a lawsuit from the originator Amgen.

Alvotech Marks Denosumab Milestone

Alvotech has reported the latest clinical trial results for its AVT03 proposed denosumab biosimilar rival to Prolia and Xgeva.

Boan Biotech Nears Denosumab Registration After Phase III Enrollment Completion

Completion of the Phase III trial may lead Boan Biotech to international registrations of denosumab, a market worth over $5.6bn globally.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel